Introducing Antygen™ COVID-19 antibody detection platforms.
Our new suite of Antygen™ SARS-CoV-2 antibody detection platforms will enable researchers, pharmaceutical companies, and vaccine developers to closely monitor the immune effects induced by COVID-19 disease, vaccines, and therapies. We built them because all of our futures now depend on the body’s ability to make antibodies to SARS-CoV-2, the virus that causes pandemic COVID-19 disease.
Four new SARS-CoV-2 antibody detection platforms.
- SARS-CoV-2 HuProt™: The world’s largest human protein library; now with SARS-CoV-2. Profile autoantibodies versus >21,000 full-length human proteins alongside SARS-CoV-2 S1 receptor-binding spike and nucleocapsid proteins.
- 2-in-1 Protein Microarray: A protein plus peptide array as reported in Nature Communications and Cellular & Molecular Immunology, this array provides deep epitope-level profiling across the most important antigens from SARS-CoV-2.
- SMI Protein Microarray: SARS-CoV-2, SARS-CoV, MERS-CoV, & Influenza proteins. Economic screening for antibodies to pandemic SARS-CoV-2 and other closely related viruses.
